| Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice (NCT04094051) | The First Affiliated Hospital with Nanjing Medical University | 2019-10-01 |
| Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (NCT04008706) | AstraZeneca | 2019-09-17 |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (NCT04716075) | Polish Lymphoma Research Group | 2019-08-19 |
| Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax (NCT04016805) | TG Therapeutics, Inc. | 2019-08-05 |
| A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment (NCT04059081) | Deok-Hwan Yang | 2019-07-09 |
| Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (NCT03960840) | Novartis Pharmaceuticals | 2019-06-26 |
| Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (NCT03986034) | National Heart, Lung, and Blood Institute (NHLBI) | 2019-06-26 |
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL (NCT03572634) | Sumitomo Pharma America, Inc. | 2019-06-10 |
| A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies (NCT03913949) | Ascentage Pharma Group Inc. | 2019-06-03 |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) (NCT03801525) | TG Therapeutics, Inc. | 2019-05-16 |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders (NCT03601819) | University of Michigan Rogel Cancer Center | 2019-05-15 |
| A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (NCT03980002) | Institute of Hematology & Blood Diseases Hospital, China | 2019-05-15 |
| Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma (NCT03870633) | Alliance for Clinical Trials in Oncology | 2019-05-14 |
| A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas (NCT03893682) | Aptose Biosciences Inc. | 2019-04-30 |
| Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. (NCT03939234) | Lars Møller Pedersen | 2019-04-26 |
| Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations (NCT03513562) | Ohio State University Comprehensive Cancer Center | 2019-03-26 |
| Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic Leukemia (NCT03971565) | Assistance Publique Hopitaux De Marseille | 2019-03-19 |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (NCT03740529) | Loxo Oncology, Inc. | 2019-03-15 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (NCT03833180) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-03-14 |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03666000) | Imugene Limited | 2019-03-11 |
| Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL (NCT03708003) | Swiss Cancer Institute | 2019-03-11 |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma (NCT03884998) | City of Hope Medical Center | 2019-02-26 |
| Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (NCT03836261) | Acerta Pharma BV | 2019-02-25 |
| Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia (NCT03701282) | National Cancer Institute (NCI) | 2019-02-12 |
| Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study (NCT03545035) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2019-02-06 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia (NCT03737981) | National Cancer Institute (NCI) | 2019-01-31 |
| Chronic Lymphocytic Leukemia Responds to Dermal Chelation (NCT03495492) | Optimum Health, Natural Healthcare Center | 2018-12-01 |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT03438344) | City of Hope Medical Center | 2018-12-01 |
| The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib (NCT03528941) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2018-11-28 |
| Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia (NCT03609593) | Nicole Lamanna | 2018-11-12 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation (NCT03734601) | Stanford University | 2018-11-05 |
| Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness (NCT03881592) | Brno University Hospital | 2018-11-01 |
| A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (NCT03734016) | BeiGene | 2018-11-01 |
| Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03516617) | Mayo Clinic | 2018-09-10 |
| Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies (NCT03671590) | TG Therapeutics, Inc. | 2018-09-10 |
| Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR (NCT03676504) | University Hospital Heidelberg | 2018-09-07 |
| Observational Study of Ibrutinib Use in CLL (NCT03633045) | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | 2018-09-01 |
| Exercise Training to Promote Resilience to Chronic Lymphocytic Leukemia (NCT04950452) | Duke University | 2018-08-22 |
| CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (NCT03560752) | City of Hope Medical Center | 2018-08-20 |
| Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia (NCT03447808) | Jennifer Woyach | 2018-08-16 |
| Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors (NCT03615105) | Memorial Sloan Kettering Cancer Center | 2018-07-25 |
| Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (NCT03524235) | Noah Merin | 2018-07-18 |
| Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS (NCT03534323) | Dana-Farber Cancer Institute | 2018-07-12 |
| A Study Of The Selective PKC-β Inhibitor MS- 553 (NCT03492125) | MingSight Pharmaceuticals, Inc | 2018-05-25 |
| Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) (NCT03207555) | M.D. Anderson Cancer Center | 2018-05-23 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758) | Brenda Cooper, MD | 2018-05-22 |
| A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL (NCT03467867) | Georgetown University | 2018-04-26 |
| Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma (NCT03501576) | Emory University | 2018-04-06 |
| Gazyva Infusion Reaction Investigation (NCT03529227) | Healthy Future | 2018-03-31 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression (NCT03480360) | Dartmouth-Hitchcock Medical Center | 2018-03-28 |
| Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL (NCT03379051) | TG Therapeutics, Inc. | 2018-03-27 |
| A Study of BNC105P Combined With Ibrutinib (NCT03454165) | Dartmouth-Hitchcock Medical Center | 2018-03-09 |
| Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia (NCT03374137) | Hoffmann-La Roche | 2018-03-09 |
| A Prognostic Tool for Early Stage CLL (NCT03436524) | Oncology Institute of Southern Switzerland | 2018-03-01 |
| A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) (NCT04771507) | Jeanette Lundin | 2018-02-23 |
| Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product (NCT03436771) | Juno Therapeutics, a Subsidiary of Celgene | 2018-02-19 |
| Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (NCT03370185) | SecuraBio | 2018-02-12 |
| Lenalidomide and Obinutuzumab for Previously Untreated CLL (NCT02371590) | University of California, San Diego | 2018-02-01 |
| A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (NCT03328273) | Acerta Pharma BV | 2018-01-31 |
| Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (NCT03310190) | AbbVie | 2018-01-10 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells (NCT03375619) | Medical College of Wisconsin | 2017-12-01 |
| Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation (NCT03153514) | German CLL Study Group | 2017-11-13 |
| Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (NCT04754035) | Paolo Ghia | 2017-11-08 |
| A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (NCT03336333) | BeiGene | 2017-10-31 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (NCT03263637) | AstraZeneca | 2017-10-24 |
| Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell (NCT03019055) | Medical College of Wisconsin | 2017-10-16 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT03204188) | National Heart, Lung, and Blood Institute (NHLBI) | 2017-09-22 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906) | Fred Hutchinson Cancer Center | 2017-09-11 |
| Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab (NCT03280160) | PETHEMA Foundation | 2017-09-07 |
| Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina (NCT03059251) | Hoffmann-La Roche | 2017-08-31 |
| Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials (NCT03207256) | TG Therapeutics, Inc. | 2017-08-09 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (NCT02952508) | Cellectar Biosciences, Inc. | 2017-07-26 |
| Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) (NCT03153202) | Joshua Brody | 2017-07-14 |
| A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies (NCT03191773) | Second Affiliated Hospital of Guangzhou Medical University | 2017-06-30 |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (NCT03162536) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2017-06-26 |
| Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies (NCT03056339) | M.D. Anderson Cancer Center | 2017-06-21 |
| Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL (NCT03128879) | M.D. Anderson Cancer Center | 2017-06-16 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers (NCT03037645) | Sunesis Pharmaceuticals | 2017-04-28 |
| Identification of Occupational Exposures in Acute Hematologic Malignancy (NCT03316209) | Centre Hospitalier Intercommunal Creteil | 2017-04-27 |
| Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) (NCT02983617) | Gilead Sciences | 2017-04-06 |
| Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (NCT02981745) | Centaurus Biopharma Co., Ltd. | 2017-04-01 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL (NCT02970318) | Acerta Pharma BV | 2017-02-02 |
| Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome (NCT02846623) | M.D. Anderson Cancer Center | 2017-01-31 |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide (NCT03088709) | Loyola University | 2017-01-18 |
| Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study (NCT03197259) | Fatih Demirkan, MD | 2017-01-01 |
| Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (NCT02968563) | Gilead Sciences | 2016-12-13 |
| Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation (NCT02950051) | German CLL Study Group | 2016-12-13 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (NCT02915224) | Hoffmann-La Roche | 2016-11-23 |
| Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects (NCT06536452) | Mayo Clinic | 2016-11-18 |
| Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 (NCT02860676) | University of California, San Diego | 2016-11-03 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers (NCT02991638) | The University of Hong Kong | 2016-11-01 |
| Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (NCT02639910) | MorphoSys AG | 2016-11-01 |
| Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies (NCT02924402) | Xencor, Inc. | 2016-10-01 |